The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Intellia's management provided investors with optimistic timelines for the NTLA-3001 study, claiming the first patient would be dosed in the second half of 2024. However, they failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference in the scientific community [1]. - The truth emerged on January 9, 2025, when Intellia announced the halting of all NTLA-3001 research and a 27% workforce reduction, indicating a shift in focus to other pharmaceutical developments [1]. Stock Price Impact - Following the announcement of the discontinuation of NTLA-3001, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to$10.20 per share on January 10, 2025, reflecting a significant loss in market value [1]. Next Steps for Shareholders - Shareholders who purchased NTLA shares during the specified class period are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs and receive updates on the case [2].